AUGMENTED OXYGEN DELIVERY THERAPEUTICS

描述：（改编自申请人的摘要）。通过 Myochlor和伊利诺伊大学的合作伙伴关系， 研究人员试图将他们先前的发现还原为实践， 能够产生新的氧转运治疗剂， 增强功能。一个完全人工合成的基因已经被构建 它允许在细菌中产生克级的人类血红蛋白， hosts.这种材料，作为孤立的，纳入血红素和组装成 功能性四聚体。通过基因改造， 合成基因，研究人员已经产生了一种新的基因， 允许四聚体人血红蛋白融合的蛋白质结构 到各种基于肽和蛋白质的生物活性 化合物. 具体地，他们提出产生蛋白质缀合物，其中人 血红蛋白四聚体通过二聚化与酶连接 人超氧化物歧化酶。生成的材料应显示 作为血液替代品的氧气输送方面的增强功能， 由于其增加的聚集体尺寸，以及一种新颖的新的 氧自由基清除功能。后期能力， 以人血红蛋白作为载体的结合物形式递送， 血管寿命，应具有重要的临床效果，在预防 创伤或心肌梗死后的再灌注损伤。 拟定商业应用：不可用

DESCRIPTION: (Adapted from the applicant's abstract). Through the partnership of Myochlor and the University of Illinois, the investigators seek to reduce to practice their previous discovery which enables the generation of novel oxygen transporting therapeutics with augmented functionality. A totally synthetic gene has been constructed which allows the gram level production of human hemoglobin in bacterial hosts. This material, as isolated, incorporates heme and assembles into a functional tetramer. Through genetic modification of this totally synthetic gene , the investigators have produced a novel gene and protein structure which allows fusion of the tetrameric human hemoglobin to a variety of peptide and protein based pharmacologically active compounds. Specifically, they propose to generate a protein conjugate wherein human hemoglobin tetramers are linked through dimerization with the enzyme human superoxide dismutase. The resulting material should display augmented function with regard to oxygen delivery as a blood substitute, due to its increased aggregate size, as well as a novel new functionality of oxygen radical scavenging. The later capacity, delivered as a conjugate with human hemoglobin as a carrier with defined vascular lifetime, should have important clinical effects in preventing reperfusion injury following trauma or myocardial infarct. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE